Fact CheckerSign in

NCT07773454Not yet recruitingPhase 1

Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors

A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors

Source: ClinicalTrials.gov · Last updated 19 Aug 2026

Brief summary (registry, in English)

The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
18 (estimated)
First submitted
12 Aug 2026
Start date
30 Sept 2026
Primary completion date
31 Jul 2028
Lead sponsor
Exelixis
NCT number
NCT07773454

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 18
  • From 30 Sept 2026 to the primary completion date, 31 Jul 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • For participants with CNS primary tumors, evidence of intracranial or intratumoral hemorrhage are excluded.

Other

  • Diagnosis of lymphoma.
  • Lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.
    • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Who the study is looking for

  • Participants must be \< 17 years old.
  • Participants must have a minimum body weight of ≥ 10 kilograms (kg) at enrollment.
  • Performance status of ≥ 50% as measured by Lansky for participants \< 16 years of age or Karnofsky for participants ≥ 16 years of age.
  • Have a relapsed or refractory solid tumor, including primary CNS tumors (excluding lymphoma).

Age in the registry: 12 months to 17 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.